89 related articles for article (PubMed ID: 1653205)
1. The inhibition of supercoiling activity of DNA gyrase from Micrococcus luteus caused by rufloxacin (MF 934) and MF 961.
Fabbri S; Broggini M; Pagella P; D'Incalci M
J Antimicrob Chemother; 1991 May; 27(5):687-9. PubMed ID: 1653205
[No Abstract] [Full Text] [Related]
2. Mechanism of action of the des-F(6) quinolone BMS-284756 measured by supercoiling inhibition and cleavable complex assays.
Wu P; Lawrence LE; Denbleyker KL; Barrett JF
Antimicrob Agents Chemother; 2001 Dec; 45(12):3660-2. PubMed ID: 11709365
[TBL] [Abstract][Full Text] [Related]
3. Stereo (C7)-dependent topoisomerase II inhibition and tumor growth suppression by a new quinolone, BO-2367.
Yoshinari T; Mano E; Arakawa H; Kurama M; Iguchi T; Nakagawa S; Tanaka N; Okura A
Jpn J Cancer Res; 1993 Jul; 84(7):800-6. PubMed ID: 8396568
[TBL] [Abstract][Full Text] [Related]
4. Discrepancy between the antibacterial activities and the inhibitory effects on Micrococcus luteus DNA gyrase of 13 quinolones.
Fu KP; Grace ME; McCloud SJ; Gregory FJ; Hung PP
Chemotherapy; 1986; 32(6):494-8. PubMed ID: 3026740
[TBL] [Abstract][Full Text] [Related]
5. Clerocidin, a terpenoid antibiotic, inhibits bacterial DNA gyrase.
McCullough JE; Muller MT; Howells AJ; Maxwell A; O'Sullivan J; Summerill RS; Parker WL; Wells JS; Bonner DP; Fernandes PB
J Antibiot (Tokyo); 1993 Mar; 46(3):526-30. PubMed ID: 8386713
[No Abstract] [Full Text] [Related]
6. 4-quinolones and the physiology of DNA gyrase.
Drlica K; Kreiswirth B
Adv Pharmacol; 1994; 29A():263-83. PubMed ID: 7826862
[No Abstract] [Full Text] [Related]
7. Inhibition by quinolones of DNA gyrase from Staphylococcus aureus.
Tanaka M; Sato K; Kimura Y; Hayakawa I; Osada Y; Nishino T
Antimicrob Agents Chemother; 1991 Jul; 35(7):1489-91. PubMed ID: 1656864
[TBL] [Abstract][Full Text] [Related]
8. Genetic profile of a nalidixic acid analog: a model for the mechanism of sister chromatid exchange induction.
Holden HE; Barett JF; Huntington CM; Muehlbauer PA; Wahrenburg MG
Environ Mol Mutagen; 1989; 13(3):238-52. PubMed ID: 2539998
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids.
Zweerink MM; Edison A
Antimicrob Agents Chemother; 1986 Apr; 29(4):598-601. PubMed ID: 3010848
[TBL] [Abstract][Full Text] [Related]
10. [Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa].
Tani M; Maebashi K; Araake M; Watabe H
Jpn J Antibiot; 2002 Dec; 55(6):882-5. PubMed ID: 12621742
[TBL] [Abstract][Full Text] [Related]
11. The in-vitro activity of two new quinolones: rufloxacin and MF 961.
Wise R; Andrews JM; Matthews R; Wolstenholme M
J Antimicrob Chemother; 1992 Jun; 29(6):649-60. PubMed ID: 1324239
[TBL] [Abstract][Full Text] [Related]
12. Rufloxacin (MF-934): in vitro and in vivo antibacterial activity.
Ravizzola G; Pinsi G; Pirali F; Colombrita D; Foresti I; Peroni L; Turano A
Drugs Exp Clin Res; 1989; 15(1):11-5. PubMed ID: 2743869
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory activity on DNA gyrase and intracellular accumulation of quinolones: structure-activity relationship of Q-35 analogs.
Ito T; Kojima K; Koizumi K; Nagano H; Nishino T
Biol Pharm Bull; 1994 Jul; 17(7):927-30. PubMed ID: 8000379
[TBL] [Abstract][Full Text] [Related]
14. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.
Takei M; Fukuda H; Kishii R; Hosaka M
Antimicrob Agents Chemother; 2001 Dec; 45(12):3544-7. PubMed ID: 11709337
[TBL] [Abstract][Full Text] [Related]
15. Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
Matrat S; Petrella S; Cambau E; Sougakoff W; Jarlier V; Aubry A
Antimicrob Agents Chemother; 2007 May; 51(5):1643-8. PubMed ID: 17325221
[TBL] [Abstract][Full Text] [Related]
16. In vitro cleavable-complex assay to monitor antimicrobial potency of quinolones.
Walton L; Elwell LP
Antimicrob Agents Chemother; 1988 Jul; 32(7):1086-9. PubMed ID: 2847641
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus.
Hoshino K; Sato K; Une T; Osada Y
Antimicrob Agents Chemother; 1989 Oct; 33(10):1816-8. PubMed ID: 2556080
[TBL] [Abstract][Full Text] [Related]
18. A new tricyclic fluoroquinolone, rufloxacin (MF-934), with interesting antibacterial and pharmacokinetic characteristics.
Segre G; Cerretani D; Cerri D; Moltoni L
Drugs Exp Clin Res; 1988; 14(12):747-54. PubMed ID: 3253051
[TBL] [Abstract][Full Text] [Related]
19. Micrococcus luteus DNA gyrase: active components and a model for its supercoiling of DNA.
Liu LF; Wang JC
Proc Natl Acad Sci U S A; 1978 May; 75(5):2098-102. PubMed ID: 276855
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of Salmonella typhi and Brucella melitensis to the new fluoroquinolone rufloxacin (MF 934).
Qadri SM; Ayub A; Ueno Y; Saldin H
Chemotherapy; 1993; 39(5):311-4. PubMed ID: 8396527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
